Search results
Showing 1081 to 1095 of 1364 results for social care
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Discontinued Reference number: GID-TA10186
Discontinued Reference number: GID-TA10196
Discontinued Reference number: GID-TA10429
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
both CRCs and the NPS. The comparison should be against standard CRC and NPS care. The trial should consider both clinical outcomes and...
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
Discontinued Reference number: GID-TA10234
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]
Discontinued Reference number: GID-TA10199
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.